A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[1] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Hideyuki Akaza
Hirotsugu Uemura
Taiji Tsukamoto
Seiichiro Ozono
Osamu Ogawa
Hideki Sakai
Mototsugu Oya
Mikio Namiki
Satoshi Fukasawa
Akito Yamaguchi
Hiroji Uemura
Yasuo Ohashi
Hideki Maeda
Atsushi Saito
Kentaro Takeda
Seiji Naito
International Journal of Clinical Oncology, 2016, 21 : 773 - 782
[2] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodriguez-Vida, Alejo
Galazi, Myria
Rudman, Sarah
Chowdhury, Simon
Sternberg, Cora N.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
[3] Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer
Yamasaki, Mutsushi
Yuasa, Takeshi
Yamamoto, Shinya
Hayashi, Tatsuro
Ogawa, Masahiro
Sakura, Mizuaki
Masuda, Hitoshi
Fukui, Iwao
Yonese, Junji
ANTICANCER RESEARCH, 2016, 36 (01) : 361 - 365
[4] Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
Schalken, Jack
Fitzpatrick, John M.
BJU INTERNATIONAL, 2016, 117 (02) : 215 - 225
[5] Safety of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel: Expanded Access in North America
Joshua, Anthony M.
Shore, Neal D.
Saad, Fred
Chi, Kim N.
Olsson, Carl A.
Emmenegger, Urban
Scholz, Mark
Berry, William
Mukherjee, Som D.
Winquist, Eric
Haas, Naomi B.
Foley, Margaret A.
Dmuchowski, Carl
Perabo, Frank
Hirmand, Mohammad
Hasabou, Nahla
Rathkopf, Dana
PROSTATE, 2015, 75 (08): : 836 - 844
[6] Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
Gacci, Mauro
Marchioni, Michele
De Francesco, Piergustavo
Natoli, Clara
Calabro, Fabio
Losanno, Tania
Gianmartin, Cito
Serni, Sergio
Doni, Laura
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Alvarez-Maestro, Mario
Scarcia, Marcello
Ludovico, Giuseppe M.
Del Bene, Gabriella
Simone, Giuseppe
Ferriero, Mariaconsiglia
Tuderti, Gabriele
Bove, Pierluigi
Laudisi, Anastasia
Carrieri, Giuseppe
Cormio, Luigi
Verze, Paolo
La Rocca, Roberto
Falsaperla, Mario
Frantellizzi, Viviana
Greco, Francesco
Di Nicola, Marta
Schips, Luigi
Cindolo, Luca
MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 489 - 497
[7] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
Baciarello, Giulia
Sternberg, Cora N.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
[8] A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
Schweizer, Michael T.
Haugk, Kathleen
McKiernan, Jozefa S.
Gulati, Roman
Cheng, Heather H.
Maes, Jessica L.
Dumpit, Ruth F.
Nelson, Peter S.
Montgomery, Bruce
McCune, Jeannine S.
Plymate, Stephen R.
Yu, Evan Y.
PLOS ONE, 2018, 13 (06):
[9] ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Ha, Y-S
Goodin, S.
DiPaola, R. S.
Kim, I. Y.
DRUGS OF TODAY, 2013, 49 (01) : 7 - 13
[10] Clinical Activity of Enzalutamide in Docetaxel-Naive and Docetaxel-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
Nadal, Rosa
Zhang, Zhe
Rahman, Hibba
Schweizer, Michael T.
Denmeade, Samuel R.
Paller, Channing J.
Carducci, Michael A.
Eisenberger, Mario A.
Antonarakis, Emmanuel S.
PROSTATE, 2014, 74 (15): : 1560 - 1568

← 1 2 3 4 5 →